Radioiodine Therapy with Recombinant Human TSH for Thyroid Cancer
Author Information
Author(s): Ivana Zagar, Andreja Schwarzbartl-Pevec, Barbara Vidergar-Kralj, Rika Horvat, Nikola Besic
Primary Institution: Institute of Oncology, Ljubljana, Slovenia
Hypothesis
Can recombinant human TSH (rhTSH) improve the efficacy of radioiodine therapy in patients with differentiated thyroid carcinoma who cannot undergo thyroid hormone withdrawal?
Conclusion
RhTSH-aided radioiodine therapy provided some therapeutic benefit in 39% of patients with metastatic differentiated thyroid carcinoma who could not be treated effectively with standard methods.
Supporting Evidence
- 39% of patients showed some therapeutic benefit from rhTSH-aided RIT.
- 61% of patients experienced disease progression despite treatment.
- Patients had a median follow-up of 50 months.
Takeaway
Doctors used a special hormone to help patients with thyroid cancer get treatment without making them feel sick. It worked for some of them.
Methodology
The study involved 18 patients who received rhTSH-aided radioiodine treatments and were followed for a median of 50 months.
Potential Biases
Observations were unblinded, which may introduce bias.
Limitations
The study was observational, had a relatively short follow-up, and lacked blinding.
Participant Demographics
The median age was 72 years, with 72% of patients over 65; 12 females and 6 males were included.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website